A model for success
We are led by a team of passionate and respected experts with proven track records of success in drug discovery and commercialization. Their knowledge and experience help foster and inspire innovation at every level of the company. Learn more about what makes us unique.
Our Board of Directors includes the executive leadership of Sumitomo Pharma Co., Ltd.
Patricia S. Andrews
Chief Executive Officer
Global Head of Oncology
Patricia S. Andrews serves as the Chief Executive Officer and Global Head of Oncology. Prior to joining Sumitomo Pharma Oncology (SMP Oncology), Ms. Andrews spent 7 years at Boston Biomedical, Inc., one of the predecessor companies, and served as Chief Executive Officer and Chief Operating Officer.
Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a U.S.-based biopharmaceutical company. In this role, she led the transition from a clinical-stage research and development organization to a successful commercial enterprise with the launch of its first-for-the-company, first-in-class, first-in-disease, orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.
Prior to her experience at Incyte, Ms. Andrews spent 17 years at Pfizer Inc., culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, at the time a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews is an Executive Officer of Sumitomo Pharma Co., Ltd. and serves on the board of GlycoMimetics [Nasdaq: GLYC]. Ms. Andrews received her M.B.A. from the University of Michigan and a B.A. from Brown University.
Masashi Murata, Ph.D.
Chief Strategy Officer
Global Strategy and Planning
Masashi Murata, Ph.D. serves as Chief Strategy Officer, Global Strategy and Planning, as well as the Interim Steward of US Global Research. In this role, he formulates and monitors the execution of corporate strategy and associated plans in support of the company’s vision, mission, and business imperatives. Prior to joining SMP Oncology, Dr. Murata served as Chief Strategic Officer, Global Strategy and Planning and Vice President of Corporate Strategy and Planning at Boston Biomedical, Inc., one of the predecessor companies.
Dr. Murata has more than 26 years of experience in the biopharmaceutical industry, leading multiple clinical development programs in Japan and managing collaborations and alliances. Dr. Murata also oversaw clinical development programs, drug discovery, and preclinical research programs at Sumitomo Pharma Co., Ltd., culminating in the role of Director in the Global Strategy Group of the Global Oncology Office. Dr. Murata also led several preclinical-stage research programs, including in-house at Sumitomo Pharma and third-party collaboration programs at AstraZeneca plc in immunology, gene therapy, and oncology.
Dr. Murata earned his Doctor of Philosophy and Faculty of Sciences degrees from Kyoto University in Kyoto, Japan, and has also co-authored articles in several peer-reviewed publications.
Jatin J. Shah, M.D.
Chief Medical Officer
Global Head of Development
Jatin J. Shah, M.D. serves as Executive Vice President, Chief Medical Officer and Global Head of Development. In this role, Dr. Shah is responsible for leading the strategic and operational aspects of clinical development including regulatory submissions and Medical Affairs for the Global Oncology pipeline.
Dr. Shah brings significant medical oncology and industry experience to SMP Oncology. Since 2017, he served as Chief Medical Officer and Executive Vice President for Karyopharm Therapeutics. In this role, he was instrumental in leading clinical research efforts that resulted in three successful sNDAs, multiple IND submissions and the development of a comprehensive solid tumor and hematological pipeline that includes early and late-stage assets. Dr. Shah also played a critical external-facing role, supporting investor relations and the CEO in raising over $500 million in a royalty deal and public and private offerings.
Previously, he worked at The University of Texas MD Anderson Cancer Center (MD Anderson), which included work as a treating physician for patients with multiple myeloma and clinical research. For nearly ten years at MD Anderson, Dr. Shah served as an Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine.
Dr. Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio, and his undergraduate degree, also from Ohio State University, in Mechanical Engineering. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah held board certification in hematology and oncology from the American Board of Internal Medicine. He has served as principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.
Stefan C. Vaughn
Senior Vice President
Chief Financial and Administrative Officer
Stefan C. Vaughn serves as Senior Vice President, Chief Financial and Administrative Officer. In this role, Mr. Vaughn leads and manages the Finance, Human Resources and Operations functions at Sumitomo Pharma Oncology (SMP Oncology). In this role, he provides strategic leadership over enterprise financial planning and reporting, and functional oversight across Finance & Accounting, Procurement, Financial Planning & Analysis, IS/IT, Human Resources, and Corporate Operations Management.
Mr. Vaughn is a seasoned executive with a global perspective and deep experience supporting fully integrated companies spanning manufacturing, consumer goods and for the last 17 years, biopharmaceuticals. Mr. Vaughn joins us from Ferring Pharmaceuticals, a research-driven global pharmaceutical company where he served as the Chief Financial Officer for US operations. Previously, he spent 11 years with Takeda Pharmaceuticals in various domestic and global Finance and Accounting leadership roles, including an expatriate assignment in Tokyo, Japan where he served as Region CFO for North Asia.
As a CFO with broad experience working in complex multinational constructs, Mr. Vaughn’s functional expertise includes leadership of various transformational initiatives encompassing M&A integrations, business process outsourcing, and IT Infrastructure & ERP system implementations.
Mr. Vaughn earned an MBA in Financial Management from DePaul University in Chicago, Illinois, and holds a Bachelor of Science in Finance from the University of Maryland, College Park, Maryland.
Steven L. Warner, Ph.D.
Senior Vice President
Head of US Research
Steven L. Warner, Ph.D. serves as Senior Vice President and Head of US Research. In this role and throughout his career, he specializes in small molecule drug discovery, new screening platforms in drug discovery and translational research focusing on cancer therapeutics. Prior to joining Sumitomo Pharma Oncology (SMP Oncology), Dr. Warner co-founded and spent 10 years at Tolero Pharmaceuticals, one of the predecessor companies, and served as Head of Research. In this role, he led or fundamentally participated in drug discovery projects that have produced ten first-in-human clinical compounds and has published dozens of peer-reviewed publications and patents from multiple drug discovery projects.
Dr. Warner has a broad background in molecular and cell biology that comes from more than two decades of drug discovery and development in both academic and pharmaceutical industry settings. Prior to co-founding Tolero Pharmaceuticals, Dr. Warner spent four years at the Center for Investigational Therapeutics, Huntsman Cancer Institute as Senior Manager, Drug Discovery. Earlier in his career, he led a team of scientists at SuperGen Inc., focusing on studies ranging from initial compound library screens to proof-of-concept studies in animal models. Dr. Warner began his career at the Translational Genomics Research Institute (TGen) where he led an effort to screen genome-wide SiRNA libraries and large chemical libraries to identify molecular targets and therapeutic agents synthetic lethal with DPC4/SMAD4 deletions in pancreatic cancer.
Dr. Warner earned his Doctor of Philosophy in Pharmaceutical Sciences from the University of Arizona and a B.S. in Biology from Brigham Young University.